Uveitis

Bibliography

• NUSSENBLATT RB, WHITCUP SM, PALESTINE AG: Uveitis: Fundamental and Clinical Practice (2nd edition). Mosby–Year Book, St. Louis, MO, USA (1996):32–38.
   Google Scholar
• • A useful introduction of basic concepts in ocular immunology.
   Google Scholar
• SPENCER WH: Ophthalmic Pathology: An Atlas and Textbook (4th edition). WB Sunders Co. (1996):1439.
   Google Scholar
• WHITCUP SM, NUSSENBLATT RB: Immunologic ocular disease. In: Clinical Immunology. Principles and Practice. Rich RR (Ed.), St. Louis, Mosby, USA (1995):579–1591.
   Google Scholar
• RUTZEN A, SMITH JA: Intraocular inflammatory diseases. In: A Clinical Guide to Comprehensive Ophthal-mology. Lee, Higginbotham (Eds.), Thieme Medical Publishers, Inc., New York, USA (1998):265–301.
   Google Scholar
• ELSCHNIG A: Studien zur sympathischen ophthal-matis: die antigene wirkung des augenpigmentes. Graefes Arch. Clin. Exp. Ohthalmol (1910) 76:509–546.
   Google Scholar
• STREILEIN JW: Regional immunity and ocular immune privilege. Chem. Immunol (1999) 73:11–38.
   PubMedGoogle Scholar
• ••Insightful review of ocular immunity.
   Google Scholar
• GERY I, STREILEIN JW: Autoimmunity in the eye and its regulation. Curr. Opin. Immunol (1994) 6(6):938–945.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the immunopathogenic mechanisms of uveitis.
   Google Scholar
• CHARUKAMNOETKANOK P, FUKUSHIMA A, WHITCUP SM et al.: Expression of ocular autoantigens in the mouse thymus. Curr. Eye Res. (1998) 17:788–792.
   PubMed Web of Science ®Google Scholar
• EGWUAGU CE, CHARUKAMNOETKANOK P, GERY I: Thymic expression of autoantigens correlates with resistance to autoimmune disease. j Immunol. (1997) 159:3109.
   PubMed Web of Science ®Google Scholar
• •This cutting edge paper was the first to demonstrate that animals expressing high levels of uveitogenic proteins in the thymus are resistant to uveitis and those expressing very low levels are susceptible to disease induction.
   Google Scholar
• HIROSE S, TANAKA T, NUSSENBLATT RB et al.: lympho-cyte responses to retinal-specific antigens in uveitis patients and healthy subjects. Curr. Eye Res. (1988) 7 (4):393–402.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB: Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indica-tions. Invest. Ophthalmol. Vis. Sci. (1991) 3 2:3131.
   Google Scholar
• WACKER WB: Experimental allergic uveitis. Invest. Ophthalmol. Vis. Sci. (1991) 3 2:3119.
   Google Scholar
• BROEKHUYSE RM, WINKENS HJ, KUHLMAN ED: Induction of experimental autoimmune uveoretinitis and pinealitis by IRBP. Comparison to uveoretinitis induced by S-antigen and opsin. Curr. Eye Res. (1986) 5:231.
   PubMed Web of Science ®Google Scholar
• CASPI RR, ROBERGE FG, CHAN CC et al.: Anew model ofautoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol (1988) 140:1490.
   PubMed Web of Science ®Google Scholar
• CASPI RR: Immune mechanisms in uveitis. Springer Semin. Immunopathol (1999) 21 (2):113–124.
   PubMed Web of Science ®Google Scholar
• WACKER WB, DONOSO LA, KALSOW CM, JR. et al.: Experimental allergic uveitis: isolation, characteriza-tion and localization of a soluble uveitopathogenic antigen from bovine retina./ Immunol. (1977) 119:1949.
   Google Scholar
• PFISTER C, CHABRE M, PLOUET MJ et al.: Retinal S antigen identified as the 48 K protein regulating light-dependent phosphodiesterase in rods. Science (1985) 228:891.
   PubMed Web of Science ®Google Scholar
• CHADER GJ: Interphotoreceptor retinoid-bindingprotein (IRBP): a model protein for molecular biological and clinically relevant studies. Invest. Ophthalmol. Vis. Sci. (1989) 30:7.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, T. KUWABARA T, F. DE MONASTERIO F et al.: S-antigen uveitis in primates: a new model for human disease. Arch. Ophthalmol. (1981) 99: 100.
   Google Scholar
• HIROSE S, KUWABARA T, NUSSENBLATT RB et al.: Uveitis induced in primates by interphotoreceptor retinoid-binding protein. Arch. Ophthalmol. (1986) 104:1698.
   Google Scholar
• EGWUAGU CE, CASPI R, MAHDI R et al.: Evidence forselective accumulation of VI38+ T lymphocytes in experimental autoimmune uveoretinitis induced by two different retinal antigens. j Immunol. (1993) 1 51:1627.
   Google Scholar
• EGWUAGU CE, BAHMANYAR S, MAHDI R et al.: Predomi-nant usage of VI38.3 T cell receptor in a T cell line that induces experimental autoimmune uveoretinitis. Clin. Immunol. & Immunopathol. (1992) 65:152.
   PubMedGoogle Scholar
• EGWUAGU CE, SMITH JA, KOZHICH AT et al.: Usage of TCR V72+ lymphocytes in experimental autoimmune uveoretinitis. Ocular Immunol. Inflamm. (19 9 6) 4(2):105–112.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM JT, KIEVIT P, GUSS RB et al.: Endotoxin-induced uveitis in rats as a model for human disease. Nature (1980) 2 8 6: 611.
   Google Scholar
• •This seminal work established EIU as model of anterior uveitis.
   Google Scholar
• COUSINS SW, GUSS RB, HOWES EL, JR. et al: Endotoxin-induced uveitis in the rats: observations on altered vascular permeability, clinical findings and histology. Exp. Eye Res. (1984) 39:665.
   PubMed Web of Science ®Google Scholar
• BROEKHUYSE RM, KUHLMANN ED, WINKENS HJ et al.: Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis. I. Induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigment epithelium. Exp. Eye Res. (1991) 52 (4):465–474.
   PubMed Web of Science ®Google Scholar
• CHAN CC, HIKITA N, DASTGHEIB K et al: Experimental melanin-protein-induced uveitis in the Lewis rat. Immunopathologic processes. Ophthalmology (1994) 101 (7):1275–1280.
   Google Scholar
• RAVIOLA G: The structural basis of blood-ocularbarriers. Exp. Eye Res. (1977) (Suppl.):27–63.
   PubMed Web of Science ®Google Scholar
• CUNHA-VAZ J: The blood-ocular barriers. Surv. Ophthalmol (1979) 23:279–294.
   PubMed Web of Science ®Google Scholar
• STREILEIN JW: Immunologic privilege of the eye. Springer Semin. Immunopathol (1999) 21(2) :95–111.
   PubMed Web of Science ®Google Scholar
• MEDAWAR PB: Immunity to homologous skin grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br. J. Exp. Pathol. (1948) 29:58.
   PubMed Web of Science ®Google Scholar
• EGAN RM, YORKEY C, BLACK R et al: In vivo behavior ofpeptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. j Immunol. (2000) 164 (9):4543–4550.
   PubMed Web of Science ®Google Scholar
• JANEWAY CA, TRAVERS P, WALPORT M et al: Immuno-biology: The Immune System in Health and Disease. Elsevier Science London, London, UK (1999).
   Google Scholar
• ••Excellent source on basic immunologic concepts. It is a wellillustrated book. Chapter 14: 'Manipulation of the Immune Response' is highly recommended.
   Google Scholar
• MCMENAMIN PG: The distribution of immune cells in the uveal tract of the normal eye. Eye (1997) 11 (Pt 2):183–193.
   PubMedGoogle Scholar
• •Comprehensive histological analysis of numbers and distri-bution of immune cells in the eye.
   Google Scholar
• WHITCUP SM, CHAN CC, LI Q et al.: Expression of cell adhesion molecules in posterior uveitis. Arch. Ophthalmol (1992) 11O(5):662–666.
   Google Scholar
• PERCOPO CM, HOOKS JJ, SHINOHARA T et al.: Cytokine-mediated activation of a neuronal retinal resident cell provokes antigen presentation. J Immunol (1990) 145 (12):4101–4107.
   PubMed Web of Science ®Google Scholar
• WILLBOLD E, LAYER PG: Muller glia cells and their possible roles during retina differentiation in vivo and in vitro. Histol. Histopathol. (1998) 13:531–552.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, KIRKMAN R, LIGHT S, BUMGARDNER et al.:Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl. J. Med. (1998) 338 (3):161–165.
   PubMed Web of Science ®Google Scholar
• GUEX-CROISIER Y, RABER J, CHAN CC et al: Humanizedantibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. (1997) 158:452–458.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, FORTIN E, SCHIFFMAN R et al.:Treatment of noninfectious intermediate and posterior uveitis with humanized anti-Tac mAb:A Phase I/11 clinical trial. Proc. Natl. Acad. Sci. USA (1999) 96:7462–7466.
   PubMed Web of Science ®Google Scholar
• •This paper describes a promising therapeutic strategy for treating uveitis.
   Google Scholar
• BOEHM U, KLAMP T, HOWARD JC: Cellular responses tointerferon-7. Ann. Rev. Immunol (1997) 15:749.
   PubMed Web of Science ®Google Scholar
• BOTTAZZO GF, PUJOL-BORRELL R, T. HANAFUSA T et al: Role of aberrant HIA-DR expression and antigen presentation in induction of endocrine autoimmu-nity. Lancet (1983) 11:1115.
   Google Scholar
• DETRICK BD, NEWSOME DA, PERCOPO CM et al: Class IIantigen expression and gamma interferon modula-tion of monocytes and retinal pigment epithelial cells from patients with retinitis pigrnentosa. Clin. Immunol. Immunopathol (1985) 36:201.
   PubMedGoogle Scholar
• HOOKS JJ, CHAN CC, DETRICK B: Identification of thelymphokines, interferon-gamma and interleukin-2, in inflammatory eye diseases. Invest. Ophthalmol Vis. Sci. (1988) 29:1444.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, LONDEI M, BUCHAN G: Interferons andautoimmunity. Interferon (1987) 9:75.
   PubMedGoogle Scholar
• EGWUAGU CE, SZTEIN J, MAHDI, RM et al.: Constitutive expression of IFN-7 in the eye exacerbates anterior uveitis and induces retinal degenerative changes in transgenic rats. Clin. Immunol. (1999) 91:196–205.
   PubMed Web of Science ®Google Scholar
• EGWUAGU CE, SZTEIN J, MAHDI RM et al.: Interferon-7 (IFNy) increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J. Immunol (1999) 162:510–517.
   PubMed Web of Science ®Google Scholar
• LAWSON BR, PRUD'HOMME GJ, CHANG Y et al.: Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. j Clin. Invest. (2000) 106(2):207–215.
   Google Scholar
• SARTANI G, SILVER PB, RIZZO LV et al.: Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest. Ophthalmol Vis. Sci. (1996) 37 (10:2211–2218.
   PubMedGoogle Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl. J. Med. (2000) 11:763–769.
   Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: Atrial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrex ate. N Engl. J. Med. (1999) 340(0253–259.
   PubMed Web of Science ®Google Scholar
• MOUSER JF, HYAMS JS: Infliximab: a novel chimericmonoclonal antibody for the treatment of Crohn's disease. Clin. Ther. (1999) 6:932–942.
   Google Scholar
• MARKHAM A, LAMB HM: Infiximab; a review of its use inthe management of rheumatoid arthritis. Drugs (2000) 59(0:1341–1359.
   PubMedGoogle Scholar
• HAMURYUDAN V, MAT C, SAIP S et al.: Thalidomide inthe treatment of the mucocutaneous lesion of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128 (6):443–450.
   PubMed Web of Science ®Google Scholar
• GUEX-CROISIER Y, PITTET N, HERBORT CP: The effects of thalidomide and supimide on endotoxin-induced uveitis in rats. Grafes Arch. Clin. Exp. Ophthalmol. (1995) 233 (2):90–93.
   PubMed Web of Science ®Google Scholar
• ENK AH, KNOP J: Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet (1997) 350:494.
   PubMed Web of Science ®Google Scholar
• GOLDBLUM R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol. (1993) 11 (Suppl. 8):S11709.
   Google Scholar
• REIS A, REINHARD T, SUNDMACHER R et al.: Mycopheno-late mofetil in ocular immunological disorders. A survey of the literature with 3 case reports. Klin. Monatsbl Augenheilkd (1998) 213(5):257–261.
   PubMed Web of Science ®Google Scholar
• LARKIN G, LIGHTMAN S: Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology (1999) 106 (2):370–374.
   Google Scholar
• ATALLA L, LINKER-ISRAELI M, STEINMAN L et al.: Inhibi-tion of autoimmune uveitis by anti-CD4 antibody. Invest. Ophthalmol. Vis. Sci. (1990) 31 (7) :1264–1270.
   PubMed Web of Science ®Google Scholar
• THURAU SR, WILDNER G, REITER C et al: Treatment of endogenous uveitis with anti-CD4 monoclonal antibody: first report. Ger. J. Ophthalmol. (1994) 3 (6):409–413.
   PubMedGoogle Scholar
• KALLENBERG CG, TERVAERT JW: New treatments of ANCA-associated vasculitis. Sarcoidosis Vasc. Diffuse Lung Dis. (2000) 17(2):125–129.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapimmune: mechanism of action immunosupressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. (1998) 31:335–340.
   PubMed Web of Science ®Google Scholar
• ROBERGE RG, KU D, CHAN CC et al.:. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr. Eye Res. (1993) 12(2):197–203.
   PubMed Web of Science ®Google Scholar
• OHIA EO, MANCINO M, KULKARNI PS: Effects of steroids and immunusuppressive drugs on endotoxin-uveitis in rabbits. J. Ocul. Pharmacol. (1992) 8(4):295–307.
   PubMedGoogle Scholar
• MARTIN D, DEBARGE R, NUSSENBLATT RB et al.: Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoreti-nitis. j Immunol. (1995) 1 5 4:922–927.
   Google Scholar
• WHITCUP SM, DEBARGE LR, CASPI RR et al.: Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin. Immunol. Immunopathol. (1 9 9 3) 67 (2):143–150.
   PubMedGoogle Scholar
• WHITCUP SM, KOZHICH AT, LOBANOFF M et al.: Blocking both E-selectin and P-selectin inhibits endotoxin-induced leukocyte infiltration into the eye. Clin. Immunol. Immunopathoi (1997) 83 (1):45–52.
   PubMedGoogle Scholar
• WHITCUP SM, CHAN CC, KOZHICH AT et al.: Blocking ICAM-1 CD54) and LFA-1 (CD11 a) inhibits experi-mental allergic conjunctivitis. an. Immunol. (1999) 93 (2):107–113.
   Google Scholar
• SCHWARTZ RS: The new immunology-the end of immunosuppressive drug therapy? N Engl. J. Med. (1999) 340(22):1754–1756.
   PubMed Web of Science ®Google Scholar
• •Very concise review of the role of dendritic cells, co-stimulation and immune suppressive therapies.
   Google Scholar
• GUINAN EC, BOUSSIOTIS VA, NEUBERG D et al.: Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. (1999) 340 (22):1704–1714.
   PubMed Web of Science ®Google Scholar
• REYNOLDS J, TAM FW, CHANDRAKER A et al.: CD28-B7blockade prevents the development of experimental autoimmune glomerulonephritis. j Clin. Invest. (2000) 105 (5):643–651.
   Google Scholar
• KATO K, SANTANA-SAHAGUN E, RASSENTI LZ et al.: The soluble CD40 ligand sCD154 in systemic lupus erythe-matosus. Clin. Invest. (1999) 1 0 4 (7):947–955.
   Google Scholar
• ZAMBIDIS ET, KURUP A, SCOTT DW: Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mot. Med. (1997) 3(3):212–224.
   Google Scholar
• AGARWAL RK, KANG Y, ZAMBIDIS E et al.: Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. j Clin. Invest. (2000) 106 (2):245–252.
   Google Scholar
• ••This paper describes a very innovative experimentalapproach to treating intraocular inflammatory diseases.
   Google Scholar
• MCPHERSON SW, ROBERTS JP, GREGERSON DS: Systemic expression of rat soluble retinal antigen induces resistance to experimental autoimmune uveoretinitis. j Immunol. (1999) 163 (8):4269–4276.
   Web of Science ®Google Scholar
• TSOKOS GC, NEPOM GT: Gene therapy in the treatment of autoimmune diseases. J. Clin. Invest. (2000) 106 (2):181–183.
   PubMed Web of Science ®Google Scholar
• COHEN IR: Physiological basis of T-cell vaccination against autoimmune disease. Cold Spring Harb. Symp. Quant. Biol. (1989) 54 (Pt 2):879–884.
   PubMedGoogle Scholar
• ZHANG J, MEDAER R, STINISSEN P et al.: MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science (1993) 261 (5127):1451–1454.
   PubMed Web of Science ®Google Scholar
• VANDENBARK AA, HASHIM G, OFFNER H: Immuniza-tion with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encepha-lomyelitis. Nature (1989) 341 (6242):541–544.
   PubMed Web of Science ®Google Scholar
• WILDNER G, HUNIG T, THURAU SR: Orally induced, peptide-specific gamma/delta TCR+ cells suppress experimental autoimmune uveitis. Eur. J. Immunol. (1996) 26(9):2140–2148.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, MITTAL KK, RYAN S et al.: Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am. Ophthalmol. (1982) 9 4 (2) :147–158.
   Google Scholar
• BOISGÉRAULT F, KHALIL I, VANNARY T et al.: Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retino-pathy. Proc. Nati Acad. Sci. USA (1996) 93:3466–3470.
   PubMed Web of Science ®Google Scholar
• WEINER HL, FRIEDMAN A, MILLER A et al.: Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann. Rev. Immunol. (1994) 12:809–837.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on oral tolerance.
   Google Scholar
• NUSSENBLATT RB, WHITCUP SM, DE SMET MD et al.: Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann. NY Acad. Sci. (1996) 13(778):325–337.
   Google Scholar
• RIZZO LV, MORAWETZ RA, MILLER-RIVERO NE et al: IL-4 and IL-10 are both required for the induction of oral tolerance. J. Immunol (1999) 162 (5):2613–2622.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, GERY I, WEINER HL et al: Treatment of uveitis by oral administration of retinal antigens: results of a Phase VII randomized masked trial. Am. J. Ophthalmol (1997) 123 (5):583–592.
   PubMed Web of Science ®Google Scholar
• WILDNER G, THURAU SR: Database screening for molecular mimicry. Immunol Today. (1997) 8(5):252.
   Google Scholar
• WILDNER G, THURAU SR: Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur. j Immunol (1994) 11:2579–2585.
   Google Scholar
• THURAU SR, DIEDRICHS-MOHRING M, FRICKE H et al.: Oral tolerance with an HLA-p eptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol. Lett. (1999) 68 (2-3):205–212.
   PubMed Web of Science ®Google Scholar
• NEUFELD AH, SAWADA A, BECKER B: Inhibition of nitric-oxide synthase 2 by aminog-uanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Nati Acad. Sci. USA (1999) 96:9944–9948.
   PubMed Web of Science ®Google Scholar
• HEGAZY HM, PEYMAN GA, LIANG C et al: Use of perfluorocarbon liquids, silicone oil and 5-fluorouracil in the management of experimental PVR. Int. Ophthalmol (1998) 22(4):239–246.
   PubMed Web of Science ®Google Scholar